Zhitong Finance App News, Wantai Biotech (603392.SH) issued an announcement. Recently, the production line of the nine-valent human papillomavirus vaccine (Escherichia coli) (“nine-valent HPV vaccine”), a wholly-owned subsidiary of the company, passed the Turkish Medicines and Medical Devices Administration (“TITCK”) GMP compliance test and obtained a GMP certificate issued by TITCK. Obtaining the GMP certificate issued by TITCK represents the first time that the company's production and quality management system has passed GMP compliance checks in PIC/S member countries, which will have a positive impact on the overseas market expansion of the nine-valent HPV vaccine.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.